COVID-19 rebound from Paxlovid likely due to insufficient exposure to drug - study
A clinical trial presented the drug's capabilities to reduce the risk of hospitalization and death from COVID by 89%.
A clinical trial presented the drug's capabilities to reduce the risk of hospitalization and death from COVID by 89%.